Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers.

This study compares the pharmacokinetics and efficacy of various subcutaneously (SC) dosed insulin analogs, including rapid‐acting, intermediate‐acting, long‐acting, and regular human insulin, using mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) models. These models were applied to data f...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacology Vol. 65; no. 8; pp. 999 - 1011
Autores principales: Chang, Yi Chien, Jusko, William J.
Formato: equations & formulas research tables/charts Journal Article
Publicado: Wiley-Blackwell Aug2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187021982&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 187021982
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00912700
        5WH
      jtl: Journal of Clinical Pharmacology
      issn: 00912700
      maglogo: Y
    pubinfo:
      dt: Aug2025
      vid: 65
      iid: 8
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        187021982
        183796145
        187021982
        187021982
        10.1002/jcph.70010
        187021982
      ppf: 999
      ppct: 12
      formats:
      tig:
        atl: Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers.
      aug:
        au:
          Chang, Yi Chien
          Jusko, William J.
        affil: Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, State University of New York at Buffalo, Buffalo NY, , USA
      sug:
        subj:
          Glucose Clamp Technique Utilization
          Insulin, Intermediate-Acting Pharmacodynamics
          Insulin, Intermediate-Acting Pharmacokinetics
          Insulin, Long-Acting Pharmacodynamics
          Insulin, Long-Acting Pharmacokinetics
          Insulin, Rapid-Acting Pharmacodynamics
          Insulin, Rapid-Acting Pharmacokinetics
          Drug Efficacy
          Research Subjects
          Human
          Funding Source
          Male
          Female
          Comparative Studies
          Dose-Response Relationship, Drug
          Insulin, Long-Acting Administration and Dosage
          Insulin Analogs and Derivatives
          Insulin Classification
          Models, Biological
          Diabetes Mellitus Drug Therapy
          Insulin Aspart
          Blood Glucose
          Insulin, Intermediate-Acting Therapeutic Use
          Insulin, Long-Acting Therapeutic Use
          Insulin, Rapid-Acting Therapeutic Use
          Male
          Female
      ab: This study compares the pharmacokinetics and efficacy of various subcutaneously (SC) dosed insulin analogs, including rapid‐acting, intermediate‐acting, long‐acting, and regular human insulin, using mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) models. These models were applied to data from euglycemic clamp studies in healthy volunteers, where insulin pharmacokinetics and its effects on glucose utilization were monitored. Data from published studies were digitized and modeled using MONOLIX (Version 2024). The PK model described insulin absorption via sequential first‐order processes and linear elimination. The PD effects were captured using a model combination of biophase, indirect, and receptor down‐regulation components. While PK parameters—especially absorption rates—varied between insulin types, a common set of nonlinear PD parameters was sought to account for dose‐related differences in glucose utilization. The maximum glucose stimulation (Smax${{{\mathrm{S}}}_{{\mathrm{max}}}}$) was 163, and the insulin concentration for a half‐maximal effect (SC50${\mathrm{S}}{{{\mathrm{C}}}_{50}}$) were 1156 pmol/L for insulin lispro, regular human insulin, neutral protamine hagedorn (NPH) insulin, and insulin glargine; 674 pmol/L for insulin aspart; and 5335 pmol/L for insulin detemir. Insulin detemir showed similar overt effects as the other insulin types but with smaller clearances and lower potency. This mechanism‐based glucose–insulin model demonstrated that most insulin analogs exhibit similar receptor‐ and transporter‐related parameters. The model, with specific PK but unified PD parameters, may enable clinical optimization of insulin therapy by highlighting differences in pharmacokinetics and operating common intrinsic glucose utilization parameters.
      pubtype: Academic Journal
      doctype:
        equations & formulas
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N